ESRRB

Across TCGA pan-cancer cohorts, ESRRB Mutation is linked to patient survival in 5 of 34 cancer types, making it a survival-associated ESRRB data layer compared with 26 for mass-spec protein.

The strongest signal is observed in uterine corpus endometrial carcinoma (UCEC), where higher ESRRB Mutation is associated with better disease-free survival. In most high-consensus cancer types, elevated ESRRB expression acts as an unfavorable survival marker, although some lineages such as UCEC and LUAD show a favorable association.

UCEC, GBM, and COAD are the cancer types where ESRRB Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
UCEC	DFS	Median	All	0.973	0.827	.012	14	view →
GBM	OS	Median	All	0.020	0.416	<.001	12	view →
COAD	OS	Median	All	0.504	0.875	.002	9	view →
PRAD	DFS	Median	All	0.085	0.774	<.001	6	view →
LUAD	DFS	Median	II,III,IV	0.950	0.667	.035	1	view →

Pink = unfavorable, green = favorable. Showing the 5 strongest of 5 lineages.

ESRRB–UCEC (DFS)

Open the UCEC breakdown →